Dusan Stefoski, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
   Ko MY, Stefoski D, Balabanov R, Vennegoor A, Wattjes MP, van Munster ET, Killestein J, Polman CH.
   Neurology.
   2011 Sep 6
   77(10):1020
   
2. Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis.
   Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Clarke R, Stefoski D, Balabanov R.
   J Neurosci.
   2011 Jun 8
   31(23):8329-41.
   
3. IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination
   Ren Z, Wang Y, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R
   J Neuroimmunol
   2011 Jan 21
   
4. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis
   Liggett T, Melnikov A, Tilwalli S, Yi Q, Chen H, Replogle C, Feng X, Reder A, Stefoski D, Balabanov R, Levenson V
   J Neurol Sci
   2010 Mar 15
   290(1-2):16-21
   
5. Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis
   Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R
   J Neuroimmune Pharmacol
   2010 Jun
   5(2):260-5
   
6. Freedom from disease activity in multiple sclerosis
   Havrdova E, Galetta S, Stefoski D, Comi G
   Neurology
   2010 Apr 27
   74 Suppl 3:S3-7
   
7. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
   Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R
   Lancet Neurol
   2009 Mar
   8(3):254-60
   
8. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study
   Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH
   Lancet Neurol
   2009 Mar
   8(3):244-53
   
9. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis
   Kaiser CC, Shukla DK, Stebbins GT, Skias DD, Jeffery DR, Stefoski D, Katsamakis G, Feinstein DL
   J Neuroimmunol
   2009 Jun 25
   211(1-2):124-30